Cargando…
Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers
Dual-modality imaging agents featuring both a radioactive complex for positron emission tomography (PET) and a fluorophore for optical fluorescence imaging (OFI) are crucial tools for reinforcing clinical diagnosis and intraoperative surgeries. We report the synthesis and characterisation of bimodal...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235045/ https://www.ncbi.nlm.nih.gov/pubmed/37264077 http://dx.doi.org/10.1038/s42004-023-00906-5 |
_version_ | 1785052620359991296 |
---|---|
author | d’Orchymont, Faustine Holland, Jason P. |
author_facet | d’Orchymont, Faustine Holland, Jason P. |
author_sort | d’Orchymont, Faustine |
collection | PubMed |
description | Dual-modality imaging agents featuring both a radioactive complex for positron emission tomography (PET) and a fluorophore for optical fluorescence imaging (OFI) are crucial tools for reinforcing clinical diagnosis and intraoperative surgeries. We report the synthesis and characterisation of bimodal mechanically interlocked rotaxane-based imaging agents, constructed via the cucurbit[6]uril CB[6]-mediated alkyne-azide ‘click’ reaction. Two synthetic routes involving four- or six-component reactions are developed to access asymmetric rotaxanes. Furthermore, by using this rapid and versatile approach, a peptide-based rotaxane targeted toward the clinical prostate cancer biomarker, prostate-specific membrane antigen (PSMA), and bearing a (68)Ga-radiometal ion complex for positron emission tomography and fluorescein as an optically active imaging agent, was synthesised. The chemical and radiochemical stability, and the cellular uptake profile of the radiolabelled and fluorescent rotaxane was evaluated in vitro where the experimental data demonstrate the viability of using an asymmetric rotaxane platform to produce dual-modality imaging agents that specifically target prostate cancer cells. |
format | Online Article Text |
id | pubmed-10235045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102350452023-06-03 Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers d’Orchymont, Faustine Holland, Jason P. Commun Chem Article Dual-modality imaging agents featuring both a radioactive complex for positron emission tomography (PET) and a fluorophore for optical fluorescence imaging (OFI) are crucial tools for reinforcing clinical diagnosis and intraoperative surgeries. We report the synthesis and characterisation of bimodal mechanically interlocked rotaxane-based imaging agents, constructed via the cucurbit[6]uril CB[6]-mediated alkyne-azide ‘click’ reaction. Two synthetic routes involving four- or six-component reactions are developed to access asymmetric rotaxanes. Furthermore, by using this rapid and versatile approach, a peptide-based rotaxane targeted toward the clinical prostate cancer biomarker, prostate-specific membrane antigen (PSMA), and bearing a (68)Ga-radiometal ion complex for positron emission tomography and fluorescein as an optically active imaging agent, was synthesised. The chemical and radiochemical stability, and the cellular uptake profile of the radiolabelled and fluorescent rotaxane was evaluated in vitro where the experimental data demonstrate the viability of using an asymmetric rotaxane platform to produce dual-modality imaging agents that specifically target prostate cancer cells. Nature Publishing Group UK 2023-06-01 /pmc/articles/PMC10235045/ /pubmed/37264077 http://dx.doi.org/10.1038/s42004-023-00906-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article d’Orchymont, Faustine Holland, Jason P. Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers |
title | Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers |
title_full | Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers |
title_fullStr | Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers |
title_full_unstemmed | Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers |
title_short | Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers |
title_sort | asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235045/ https://www.ncbi.nlm.nih.gov/pubmed/37264077 http://dx.doi.org/10.1038/s42004-023-00906-5 |
work_keys_str_mv | AT dorchymontfaustine asymmetricrotaxanesasdualmodalitysupramolecularimagingagentsfortargetingcancerbiomarkers AT hollandjasonp asymmetricrotaxanesasdualmodalitysupramolecularimagingagentsfortargetingcancerbiomarkers |